Suppr超能文献

细胞周期蛋白D1调节因子PRKN和FBX4作为散发性甲状旁腺腺瘤候选肿瘤抑制因子的分子分析

Molecular analysis of cyclin D1 modulators PRKN and FBX4 as candidate tumor suppressors in sporadic parathyroid adenomas.

作者信息

Brewer Kelly, Nip Isabel, Bellizzi Justin, Costa-Guda Jessica, Arnold Andrew

机构信息

Center for Molecular Oncology, University of Connecticut School of Medicine, Farmington, Connecticut, USA.

Center for Regenerative Medicine and Skeletal Development, Department of Reconstructive Sciences, University of Connecticut School of Dental Medicine, Farmington, Connecticut, USA.

出版信息

Endocr Connect. 2021 Mar;10(3):302-308. doi: 10.1530/EC-21-0055.

Abstract

OBJECTIVE

Primary hyperparathyroidism is most often caused by a sporadic single-gland parathyroid adenoma (PTA), a tumor type for which cyclin D1 is the only known and experimentally validated oncoprotein. However, the molecular origins of its frequent overexpression have remained mostly elusive. In this study, we explored a potential tumorigenic mechanism that could increase cyclin D1 stability through a defect in molecules responsible for its degradation.

METHODS

We examined two tumor suppressor genes known to modulate cyclin D1 ubiquitination, PRKN and FBXO4 (FBX4), for evidence of classic two-hit tumor suppressor inactivation within a cohort of 82 PTA cases. We examined the cohort for intragenic inactivating and splice site mutations by Sanger sequencing and for locus-associated loss of heterozygosity (LOH) by microsatellite analysis.

RESULTS

We identified no evidence of bi-allelic tumor suppressor inactivation of PRKN or FBXO4 via inactivating mutation or splice site perturbation, neither in combination with nor independent of LOH. Among the 82 cases, we encountered previously documented benign single nucleotide polymorphisms (SNPs) in 35 tumors at frequencies similar to those reported in the germlines of the general population. Eight cases exhibited intragenic LOH at the PRKN locus, in some cases extending to cover at least an additional 1.7 Mb of chromosome 6q25-26. FBXO4 was not affected by LOH.

CONCLUSION

The absence of evidence for specific bi-allelic inactivation in PRKN and FBXO4 in this sizeable cohort suggests that these genes only rarely, if ever, serve as classic driver tumor suppressors responsible for the growth of PTAs.

摘要

目的

原发性甲状旁腺功能亢进最常见的病因是散发性单发性甲状旁腺腺瘤(PTA),细胞周期蛋白D1是这种肿瘤类型中唯一已知且经实验验证的癌蛋白。然而,其频繁过表达的分子起源大多仍不清楚。在本研究中,我们探索了一种潜在的致瘤机制,该机制可能通过负责其降解的分子缺陷来增加细胞周期蛋白D1的稳定性。

方法

我们检测了两个已知可调节细胞周期蛋白D1泛素化的肿瘤抑制基因,PRKN和FBXO4(FBX4),以寻找82例PTA病例队列中经典双打击肿瘤抑制失活的证据。我们通过桑格测序检测队列中的基因内失活和剪接位点突变,并通过微卫星分析检测位点相关的杂合性缺失(LOH)。

结果

我们未发现通过失活突变或剪接位点扰动导致PRKN或FBXO4双等位基因肿瘤抑制失活的证据,无论是与LOH联合还是独立于LOH。在82例病例中,我们在35个肿瘤中发现了先前记录的良性单核苷酸多态性(SNP),其频率与普通人群种系中报道的频率相似。8例在PRKN基因座表现出基因内LOH,在某些情况下延伸至至少覆盖6号染色体6q25 - 26的另外1.7 Mb。FBXO4不受LOH影响。

结论

在这个相当大的队列中,没有证据表明PRKN和FBXO4存在特定的双等位基因失活,这表明这些基因即使曾经作为导致PTA生长的经典驱动肿瘤抑制基因,也非常罕见。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fed9/8052572/8a25387854c3/EC-21-0055fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验